MALDI-TOF MS-Based Methods for Rapid Antimicrobial Susceptibility Testing

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• MALDI-TOF MS-based antimicrobial susceptibility testing (AST) accelerates resistance detection by analyzing bacterial protein profiles after brief antibiotic exposure, delivering results in hours instead of days.
• Laboratories should match method choice to their specific workflow, weighing resistance mechanism detection, semiquantitative growth analysis, and machine learning approaches against available instrumentation and validation capacity.
• Current evidence shows variable accuracy across studies, so confirmatory phenotypic testing remains necessary for clinical decisions until methods are standardized and externally validated.

The Clinical Problem of Slow Susceptibility Results

Antimicrobial resistance ranks among the most serious threats to modern medicine. The World Health Organization describes antimicrobial resistance as a process where microorganisms develop the ability to survive exposure to drugs designed to eliminate them, undermining treatment effectiveness and complicating patient management across healthcare systems worldwide. The clinical consequences extend beyond individual treatment failure to include prolonged hospitalizations, increased mortality, and rising healthcare expenditures.

Conventional antimicrobial susceptibility testing relies on visible bacterial growth in the presence of antibiotics. Broth microdilution and disk diffusion methods require incubation periods of 16 to 24 hours after pure culture isolation, creating a substantial delay between organism identification and susceptibility data. During this window, clinicians must prescribe empiric therapy without knowing whether the infecting organism will respond. For patients with severe infections, this uncertainty can mean the difference between rapid recovery and deteriorating clinical status.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry has already transformed bacterial identification in clinical laboratories. The American Society for Microbiology recognizes MALDI-TOF MS as a standard tool in contemporary laboratory practice, with the technology largely replacing traditional biochemical testing because of its speed, accuracy, and low per-sample cost after initial instrument investment. The same technology now offers a pathway to accelerate susceptibility testing by detecting how bacterial protein profiles change when organisms are exposed to antibiotics.

The core principle is straightforward. When susceptible bacteria encounter an antibiotic, their growth slows or stops, and their protein production shifts accordingly. Resistant bacteria continue replicating and producing proteins similar to untreated controls. MALDI-TOF MS can detect these differences in mass spectra within hours, providing susceptibility information that conventionally requires overnight incubation.

How MALDI-TOF MS Detects Bacterial Proteins

MALDI-TOF MS works by ionizing bacterial proteins, primarily ribosomal proteins that are abundant and conserved within species, then measuring the time these ions take to travel through a vacuum tube toward a detector. The resulting mass spectrum displays peaks corresponding to different protein masses, creating a molecular fingerprint unique to each bacterial species.

The instrument generates spectra from colonies grown on solid media or from liquid cultures. A small amount of bacterial biomass is applied to a target plate, mixed with a matrix solution that absorbs laser energy, and allowed to crystallize. The laser desorbs and ionizes the proteins, and the time-of-flight detector records their mass-to-charge ratios. Reference databases match the resulting spectrum against known patterns for species-level identification.

For susceptibility testing applications, the same spectral technology measures quantitative differences in protein content. When bacteria are incubated with antibiotics for short periods, susceptible strains show reduced overall protein mass compared to untreated controls. Resistant strains continue accumulating protein at rates similar to controls. These semiquantitative measurements form the basis for rapid susceptibility determination.

The technology requires careful attention to sample preparation. Spectral quality depends on the purity and quantity of bacterial biomass, the extraction procedure, and the matrix solution used. Laboratories must follow established protocols to ensure consistent results across runs and operators.

Approaches to MALDI-TOF MS-Based Susceptibility Testing

Direct Detection of Resistance Mechanisms

One strategy identifies specific resistance mechanisms by their characteristic spectral signatures. Certain resistance mechanisms produce detectable protein changes that appear as unique peaks or altered spectral patterns. For example, enzymes that modify or degrade antibiotics may generate identifiable protein peaks in the mass spectrum.

This approach offers the advantage of speed, since detection can be performed directly on the initial culture without additional incubation steps. Results may be available within minutes of obtaining a pure isolate. The approach works best for well-characterized resistance mechanisms where the spectral signature is known and consistent across strains.

The primary limitation is scope. Many resistance mechanisms do not produce detectable spectral changes, and the approach requires prior knowledge of which mechanisms to target. Laboratories must know what they are looking for before they can find it, making this strategy less useful for detecting novel or unexpected resistance.

Semiquantitative Growth Curve Analysis

A second approach measures bacterial growth in the presence of antibiotics using MALDI-TOF MS as the detection readout. Bacteria are incubated briefly with antibiotics, typically for 2 to 4 hours, and the resulting protein mass is measured by mass spectrometry. Susceptible bacteria show reduced protein accumulation compared to untreated controls, while resistant bacteria continue to grow.

This approach mirrors the logic of conventional broth-based susceptibility testing but replaces turbidity readings with mass spectral measurements. The shorter incubation period enables same-day results, a substantial improvement over conventional methods. The method can theoretically be applied to any antibiotic-bacteria combination, making it more flexible than resistance mechanism detection.

The semiquantitative approach demands rigorous standardization. Inoculum size, incubation time, antibiotic concentration, and growth conditions all influence the results. The mass spectral signal must be calibrated to accurately reflect bacterial biomass. Variations in any parameter can compromise reliability, requiring strict adherence to standard operating procedures.

Machine Learning-Assisted Spectral Analysis

Machine learning represents the newest frontier in MALDI-TOF MS-based susceptibility testing. These methods use computational algorithms to identify patterns in mass spectra that correlate with resistance or susceptibility, without requiring prior knowledge of specific resistance mechanisms. The algorithms learn from large datasets of spectra with known susceptibility outcomes, then apply that learning to predict resistance in new samples.

A systematic review published in Clinical Microbiology and Infection examined machine learning applications for MALDI-TOF MS analysis. The review found that Support Vector Machines, Genetic Algorithms, Artificial Neural Networks, and Quick Classifiers were the most frequently used algorithms for antimicrobial susceptibility testing applications. However, the quality of the reviewed studies ranged from poor to very good, and only a small proportion validated their algorithms on independent datasets.

A 2025 review in Frontiers in Cellular and Infection Microbiology surveyed progress in combining MALDI-TOF MS with machine learning for antimicrobial resistance prediction. The review identified critical workflow steps including raw data acquisition, data preprocessing, algorithm selection, and hyperparameter optimization. Large-scale datasets were found to better reflect true resistance status, but managing high-dimensional data presents significant challenges.

The review noted that stacking ensemble learning methods, which combine multiple algorithms, can achieve better predictive performance than individual models. Model performance and generalizability are more effectively assessed using metrics such as the Area Under the Receiver Operating Characteristic Curve (AUROC). Model interpretation tools help users understand the decision-making process, increasing transparency and acceptability.

Current challenges include insufficient sample sizes, inadequate data standardization, and limited model generalizability. These limitations mean that machine learning approaches require extensive validation before they can be implemented in clinical laboratories.

At a Glance: Comparison of MALDI-TOF MS AST Approaches

Laboratory Workflow Integration

Sample Preparation and Quality Considerations

Successful MALDI-TOF MS-based AST begins with proper sample preparation. The quality of mass spectra depends on the purity and quantity of the bacterial sample. Laboratories should follow established protocols for culture growth and sample preparation to ensure consistent results.

The American Type Culture Collection provides authenticated bacterial strains that serve as quality controls for susceptibility testing. Using reference strains with known susceptibility profiles helps laboratories verify that their MALDI-TOF MS-based AST methods produce accurate results. Quality control strains should be tested alongside clinical isolates to monitor assay performance over time.

Biosafety considerations are paramount when working with clinical bacterial isolates. The Biosafety in Microbiological and Biomedical Laboratories manual from the CDC and NIH provides guidance on risk assessment, containment, and decontamination procedures. Laboratories must follow appropriate biosafety levels based on the organisms being handled and the procedures being performed.

Workflow Steps for Implementation

Laboratories considering MALDI-TOF MS-based AST should follow a structured implementation process. The first step is to define the clinical need and determine which bacterial species and antibiotics are priorities. Not all organisms and antibiotic combinations may be suitable for MALDI-TOF MS-based testing.

The second step is to validate the method against established reference methods. The Clinical and Laboratory Standards Institute provides the framework for susceptibility testing validation. Laboratories should test a panel of well-characterized isolates with known susceptibility profiles to assess the accuracy, reproducibility, and reliability of the MALDI-TOF MS-based method.

The third step is to establish standard operating procedures that document every aspect of the workflow, from sample preparation to data interpretation. These procedures should include detailed instructions for instrument calibration, quality control, and result reporting.

The fourth step is to train laboratory personnel. MALDI-TOF MS-based AST requires different skills than conventional susceptibility testing. Technologists must understand the principles of mass spectrometry, data interpretation, and the limitations of the method.

The fifth step is to integrate the method into the laboratory's routine workflow. This includes determining how results will be reported, how they will be communicated to clinicians, and how they will be documented for quality assurance purposes.

Data Management and Interpretation

MALDI-TOF MS-based AST generates complex data that requires careful interpretation. The mass spectra contain thousands of data points, and distinguishing meaningful patterns from background noise requires sophisticated analytical approaches.

For resistance mechanism detection, interpretation involves comparing the test spectrum to reference spectra from strains with known resistance mechanisms. The presence of characteristic peaks or spectral patterns indicates the presence of the corresponding resistance mechanism.

For semiquantitative growth curve analysis, interpretation involves comparing the protein mass of antibiotic-treated samples to untreated controls. The ratio of treated to untreated mass indicates the degree of growth inhibition. A threshold must be established to classify isolates as susceptible or resistant.

For machine learning approaches, interpretation is performed by the algorithm, which outputs a prediction of susceptibility or resistance. However, laboratories must understand the basis for these predictions to assess their reliability. Model interpretation tools can help identify which spectral features contributed to the prediction.

Practical Implementation Steps

Step 1: Assess Laboratory Needs and Capabilities

Laboratories should evaluate their current workflow to determine whether MALDI-TOF MS-based AST would provide meaningful benefits. Key considerations include the volume of susceptibility testing performed, the turnaround time requirements, and the availability of MALDI-TOF MS instrumentation.

Laboratories that already use MALDI-TOF MS for organism identification can leverage the existing instrument for susceptibility testing with minimal additional capital investment. The incremental cost of susceptibility testing is primarily in reagents, software, and personnel time.

Step 2: Select the Appropriate Approach

The choice of approach depends on the laboratory's specific needs and the organisms being tested. Resistance mechanism detection is appropriate when the clinically relevant resistance mechanisms are well characterized and produce detectable spectral signatures. Semiquantitative growth curve analysis is more flexible but requires more extensive validation. Machine learning approaches offer the greatest potential but require substantial data and computational resources.

Step 3: Validate the Method

Validation is essential before implementing any new diagnostic method. Laboratories should test a panel of isolates with known susceptibility profiles, including both susceptible and resistant strains. The validation panel should include isolates with diverse resistance mechanisms and genetic backgrounds to assess the method's robustness.

Validation metrics should include sensitivity, specificity, positive predictive value, and negative predictive value compared to the reference method. Categorical agreement and essential agreement should be calculated according to Clinical and Laboratory Standards Institute guidelines.

Step 4: Establish Quality Control Procedures

Quality control is critical for ensuring the reliability of MALDI-TOF MS-based AST results. Laboratories should test quality control strains with each batch of clinical samples. The American Type Culture Collection provides reference strains with documented susceptibility profiles that are suitable for quality control purposes.

Quality control results should be documented and reviewed regularly to detect trends that might indicate problems with the assay. Instrument performance should be monitored through routine calibration and maintenance.

Step 5: Train Personnel and Document Procedures

All personnel performing MALDI-TOF MS-based AST should receive comprehensive training on the principles of the method, the operation of the instrument, and the interpretation of results. Training should include hands-on practice with known samples and assessment of competency.

Standard operating procedures should be documented and readily available to all personnel. The procedures should include detailed instructions for every step of the workflow, from sample preparation to result reporting.

Records and Measurements

Essential Data to Document

Laboratories implementing MALDI-TOF MS-based AST should maintain comprehensive records to support quality assurance and continuous improvement. The following data should be documented for each test:

• Patient or sample identifier
• Organism identification and source
• Antibiotics tested and concentrations used
• Incubation conditions, including time and temperature
• MALDI-TOF MS instrument settings and calibration data
• Raw spectral data and processed results
• Quality control results for the batch
• Final interpretation and any comments

Performance Metrics to Track

Laboratories should track key performance indicators to monitor the ongoing reliability of their MALDI-TOF MS-based AST methods. These metrics include:

• Turnaround time from sample receipt to result
• Categorical agreement with reference methods
• Essential agreement with reference methods
• Rates of indeterminate or uninterpretable results
• Rates of major errors (susceptible reported as resistant)
• Rates of very major errors (resistant reported as susceptible)

Tracking these metrics over time helps laboratories identify problems early and take corrective action before they affect patient care.

Correlation with Conventional Methods

MALDI-TOF MS-based AST results should be correlated with conventional susceptibility testing results to ensure ongoing accuracy. Laboratories should periodically test a subset of isolates using both methods and compare the results. Discrepancies should be investigated to determine the cause and whether the MALDI-TOF MS-based method requires adjustment.

Common Failure Patterns and Troubleshooting

Spectral Quality Issues

Poor spectral quality is a common cause of MALDI-TOF MS-based AST failure. Low signal intensity, high background noise, and inconsistent peak patterns can all compromise result accuracy. These issues often stem from problems with sample preparation, including insufficient bacterial biomass, contamination with media components, or improper extraction procedures.

Laboratories should monitor spectral quality metrics and establish criteria for acceptable spectra. Samples that fail quality checks should be reprocessed or tested by an alternative method.

Standardization Problems

Inconsistent results can occur when standardization parameters vary between runs. Inoculum size, incubation time, antibiotic concentration, and growth conditions all affect the outcome of semiquantitative growth curve analysis. Laboratories must adhere strictly to standard operating procedures to minimize run-to-run variability.

Data Interpretation Challenges

Interpreting MALDI-TOF MS-based AST results requires expertise and judgment. Resistance mechanism detection may produce ambiguous results when multiple mechanisms are present or when the spectral signature is weak. Machine learning predictions may be difficult to interpret when the basis for the prediction is not clear.

Laboratories should establish clear criteria for result interpretation and have a process for resolving ambiguous cases. When results are uncertain, confirmatory testing with conventional methods should be performed.

Validation Gaps

MALDI-TOF MS-based AST methods may perform well for the organisms and antibiotics included in the validation panel but poorly for others. Laboratories should be cautious about extending the method to organisms or antibiotics not included in the original validation. Additional validation should be performed before expanding the test menu.

Evidence Limitations and Research Gaps

Current State of Evidence

The evidence base for MALDI-TOF MS-based AST is still developing. A systematic review published in Clinical Microbiology and Infection identified only nine studies that used machine learning for antimicrobial susceptibility testing, compared to 27 studies for species identification. The quality of these studies ranged from poor to very good, with only a small proportion validating their algorithms on independent datasets.

The 2025 review in Frontiers in Cellular and Infection Microbiology highlighted several persistent challenges. Insufficient sample sizes limit the statistical power of many studies. Inadequate data standardization makes it difficult to compare results across studies or to apply algorithms developed in one laboratory to data from another. Limited model generalizability means that algorithms may not perform well on isolates from different geographic regions or clinical settings.

Specific Evidence Gaps

Several specific evidence gaps need to be addressed before MALDI-TOF MS-based AST can be widely adopted. First, more studies are needed that directly compare different MALDI-TOF MS-based AST approaches to determine which is most accurate and reliable. Second, studies are needed that evaluate the clinical impact of rapid susceptibility results on patient outcomes, such as time to appropriate therapy, length of hospital stay, and mortality. Third, studies are needed that assess the cost-effectiveness of MALDI-TOF MS-based AST compared to conventional methods.

Implications for Laboratory Practice

Given the current evidence limitations, laboratories should approach MALDI-TOF MS-based AST with appropriate caution. The method shows promise for reducing turnaround times, but it should not replace conventional susceptibility testing until its accuracy and reliability are well established for the specific organisms and antibiotics being tested.

Laboratories that implement MALDI-TOF MS-based AST should do so as an adjunct to conventional methods, using rapid results to guide initial therapy while awaiting confirmatory results. This approach balances the benefits of rapid results with the safety of established methods.

Species-Specific Considerations

Fastidious Organisms

Fastidious organisms present unique challenges for MALDI-TOF MS-based AST. These organisms have complex nutritional requirements and grow slowly, making it difficult to obtain sufficient biomass for analysis within a clinically useful timeframe.

A study published in Antimicrobial Agents and Chemotherapy examined antimicrobial susceptibilities of nutritionally variant streptococci, including Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans. These fastidious Gram-positive cocci are important causes of bacteremia and infective endocarditis. The study used MALDI-TOF MS for species-level identification of clinical isolates and performed susceptibility testing using the broth microdilution method described in the Clinical and Laboratory Standards Institute M45 guideline.

The study demonstrated important species-related differences in susceptibility to penicillin, cephalosporins, carbapenems, and daptomycin. These findings highlight the importance of accurate species identification, which MALDI-TOF MS provides, for interpreting susceptibility results. However, the study used conventional susceptibility testing methods, underscoring that MALDI-TOF MS-based AST for fastidious organisms remains an area of ongoing research.

Gram-Positive and Gram-Negative Bacteria

The performance of MALDI-TOF MS-based AST may differ between Gram-positive and Gram-negative bacteria. These organisms have different cell wall structures and protein profiles, which can affect spectral quality and the detectability of resistance mechanisms.

Gram-negative bacteria, particularly Enterobacterales, are a major focus of antimicrobial resistance surveillance because of the spread of carbapenem resistance. MALDI-TOF MS-based detection of carbapenemase production has been explored as a rapid method for identifying these high-priority resistant organisms.

Gram-positive organisms, including Staphylococcus aureus and Enterococcus species, present different challenges. Methicillin resistance in S. aureus and vancomycin resistance in enterococci are clinically important resistance mechanisms that may be detectable through MALDI-TOF MS analysis.

Polymicrobial Samples

MALDI-TOF MS-based AST is designed for testing pure cultures. Polymicrobial samples, which contain multiple bacterial species, cannot be reliably tested because the spectral data represent a mixture of organisms. Laboratories must ensure that samples are pure before performing MALDI-TOF MS-based AST.

Quality Control and Assurance

Reference Strains and Controls

Quality control is essential for ensuring the reliability of MALDI-TOF MS-based AST. Reference strains with known susceptibility profiles should be tested alongside clinical isolates to verify that the assay is performing correctly.

The American Type Culture Collection maintains a collection of authenticated bacterial strains that are suitable for quality control purposes. These strains have documented susceptibility profiles and are widely used in clinical laboratories. Using authenticated reference strains helps ensure that quality control results are meaningful and comparable across laboratories.

Instrument Calibration and Maintenance

MALDI-TOF MS instruments require regular calibration and maintenance to produce reliable spectra. Calibration ensures that mass measurements are accurate, which is essential for comparing spectra to reference databases and for detecting resistance-associated spectral features.

Laboratories should follow the manufacturer's recommendations for instrument calibration and maintenance. Calibration should be performed at regular intervals and whenever instrument performance is suspect. Maintenance records should be documented and reviewed as part of the quality assurance program.

Proficiency Testing

Participation in proficiency testing programs helps laboratories assess their performance against other laboratories using the same methods. Proficiency testing involves testing unknown samples and comparing results to expected values.

The American Society for Microbiology provides educational resources and professional development opportunities for laboratory professionals, including information on proficiency testing and quality assurance. Laboratories should participate in relevant proficiency testing programs to monitor the ongoing accuracy of their MALDI-TOF MS-based AST methods.

Biosafety and Laboratory Safety

Risk Assessment

Working with clinical bacterial isolates carries inherent biosafety risks. The Biosafety in Microbiological and Biomedical Laboratories manual from the CDC and NIH provides comprehensive guidance on risk assessment, containment, and decontamination.

Laboratories performing MALDI-TOF MS-based AST should conduct a thorough risk assessment that considers the organisms being handled, the procedures being performed, and the potential for aerosol generation. Sample preparation steps, including centrifugation and vortexing, can generate aerosols that may contain infectious organisms.

Containment and Decontamination

Appropriate containment measures should be in place to protect laboratory personnel from exposure to infectious agents. This includes the use of biological safety cabinets for procedures that may generate aerosols, appropriate personal protective equipment, and proper waste disposal procedures.

Decontamination procedures should be established for spills and for equipment that comes into contact with clinical samples. The CDC and NIH biosafety guidance provides recommendations for decontamination agents and procedures.

Training and Emergency Procedures

All laboratory personnel should receive training on biosafety procedures and emergency response. This includes training on the proper use of personal protective equipment, the handling of spills, and the procedures for reporting exposures.

Emergency procedures should be documented and posted in the laboratory. Personnel should know how to respond to needlesticks, splashes, and other potential exposures to infectious materials.

Regulatory and Standards Context

CLSI Standards

The Clinical and Laboratory Standards Institute develops and publishes standards for antimicrobial susceptibility testing. These standards provide standardized methods, interpretive criteria, and quality control requirements that ensure results are reliable and clinically meaningful.

CLSI standards are widely used in the United States and internationally. Laboratories implementing MALDI-TOF MS-based AST should be familiar with relevant CLSI standards and should design their validation and quality control procedures to align with these standards.

FDA and Regulatory Oversight

In the United States, diagnostic tests used in clinical laboratories may be subject to regulation by the Food and Drug Administration. MALDI-TOF MS-based AST methods that are commercially marketed as diagnostic tests require FDA clearance or approval.

Laboratories that develop their own MALDI-TOF MS-based AST methods may be subject to CLIA regulations, which establish quality standards for laboratory testing. The specific regulatory requirements depend on the nature of the test and how it is used.

International Standards

The World Health Organization provides global guidance on antimicrobial resistance surveillance and stewardship. WHO emphasizes the importance of accurate and timely susceptibility testing for guiding treatment decisions and monitoring resistance trends.

Laboratories in different countries may be subject to different regulatory requirements. Laboratories should be aware of the applicable regulations in their jurisdiction and should ensure that their MALDI-TOF MS-based AST methods comply with these requirements.

Professional Escalation Criteria

When to Confirm with Conventional Methods

MALDI-TOF MS-based AST results should be confirmed with conventional methods in certain situations. These include:

• When the result is unexpected based on the organism's typical susceptibility profile
• When the result has major therapeutic implications, such as resistance to a last-resort antibiotic
• When the spectral quality is poor or the result is ambiguous
• When the organism or antibiotic combination has not been well validated for MALDI-TOF MS-based testing
• When the result will be used for epidemiological or surveillance purposes

When to Seek Expert Consultation

Laboratories should seek expert consultation when they encounter unusual results or when they are considering expanding their MALDI-TOF MS-based AST test menu. The American Society for Microbiology provides resources and networking opportunities that can help laboratories connect with experts in the field.

Expert consultation may be particularly valuable when interpreting results for organisms with complex resistance mechanisms or when evaluating the suitability of MALDI-TOF MS-based AST for new applications.

When to Report to Public Health Authorities

Certain resistance findings have public health implications and should be reported to appropriate authorities. The World Health Organization emphasizes the importance of surveillance for detecting emerging resistance threats. Laboratories should be familiar with local reporting requirements for notifiable resistant organisms.

Future Directions and Emerging Applications

Integration with Genomic Data

The integration of MALDI-TOF MS data with genomic information represents a promising direction for antimicrobial resistance prediction. Genomic data can provide definitive information about resistance genes, while MALDI-TOF MS provides rapid phenotypic information. Combining these approaches could improve the accuracy and speed of resistance detection.

The NCBI Pathogen Detection program provides a platform for sharing and analyzing genomic data from bacterial pathogens. This resource could support the development and validation of MALDI-TOF MS-based AST methods by providing access to well-characterized isolates with known resistance profiles.

Expansion of Machine Learning Applications

Machine learning approaches for MALDI-TOF MS-based AST are likely to expand as more data become available and computational methods improve. The 2025 review in Frontiers in Cellular and Infection Microbiology identified several promising directions, including the use of stacking ensemble methods and the development of model interpretation tools.

However, the review also emphasized the need for larger datasets, better data standardization, and more rigorous external validation. These requirements will necessitate collaboration between laboratories and the development of shared data repositories.

Point-of-Care Applications

The development of portable MALDI-TOF MS instruments could enable point-of-care susceptibility testing in settings where conventional laboratory infrastructure is limited. This could be particularly valuable in low-resource settings where antimicrobial resistance is a growing concern.

However, significant technical and regulatory challenges must be overcome before point-of-care MALDI-TOF MS-based AST becomes a reality. The instruments must be robust, easy to use, and affordable, and the methods must be validated for use by non-specialist operators.

Decision Framework for Laboratory Implementation

Assessment Questions

Laboratories considering MALDI-TOF MS-based AST should answer the following questions before making implementation decisions:

1. What is the current turnaround time for susceptibility testing, and how would faster results improve patient care?
2. Which organisms and antibiotics are priorities for rapid susceptibility testing?
3. Does the laboratory already have MALDI-TOF MS instrumentation and expertise?
4. What is the expected sample volume for MALDI-TOF MS-based AST?
5. What resources are available for validation, training, and quality control?
6. How will MALDI-TOF MS-based AST results be integrated with conventional testing?

Implementation Decision Matrix

Phased Implementation Approach

A phased approach to implementation can help laboratories manage risk and build experience gradually. The first phase could involve using MALDI-TOF MS-based AST for a limited set of organisms and antibiotics where the evidence is strongest. The second phase could expand the test menu as validation data accumulate. The third phase could integrate MALDI-TOF MS-based AST into routine workflow with ongoing quality monitoring.

Building a Practical Validation and Troubleshooting Framework for MALDI-TOF MS-Based AST

Establishing a Method Verification Protocol

Before any MALDI-TOF MS-based AST method enters routine use, laboratories must verify that it performs acceptably for their specific organism panel and antibiotic menu. The Clinical and Laboratory Standards Institute provides the framework for susceptibility testing validation, and the same principles apply to MALDI-TOF MS-based approaches. A structured verification protocol should include a minimum of 30 to 50 well-characterized isolates per organism group, with an even distribution of susceptible and resistant strains. The American Type Culture Collection provides authenticated reference strains with documented susceptibility profiles that serve as the backbone of this verification panel.

The verification panel should include isolates with diverse resistance mechanisms and genetic backgrounds. For example, if the laboratory plans to test Enterobacterales for carbapenem resistance, the panel should include strains producing different carbapenemase types, such as KPC, NDM, and OXA-48-like enzymes, alongside susceptible controls. This diversity ensures that the method detects resistance broadly instead of recognizing only a single mechanism. The panel should also include isolates with borderline susceptibility profiles, since these are the most challenging to classify correctly and the most likely to reveal method limitations.

Verification results should be analyzed using categorical agreement and essential agreement metrics. Categorical agreement compares the susceptibility category assigned by the MALDI-TOF MS-based method to the reference method result. Essential agreement compares the minimum inhibitory concentration values within one doubling dilution. The Clinical and Laboratory Standards Institute guidance recommends that new methods achieve at least 90 percent categorical agreement and 90 percent essential agreement for each organism-antibiotic combination before implementation. Major errors, where a susceptible isolate is reported as resistant, should not exceed 3 percent. Very major errors, where a resistant isolate is reported as susceptible, should not exceed 1.5 percent for the organism-antibiotic combinations tested.

Creating a Batch-Level Quality Control System

Quality control for MALDI-TOF MS-based AST requires a different approach than conventional susceptibility testing because the assay measures spectral changes instead of growth inhibition. Each batch of clinical samples should include at least one susceptible reference strain and one resistant reference strain for each organism group being tested. These controls verify that the instrument detects the expected spectral differences between susceptible and resistant organisms after antibiotic exposure.

The quality control strains should be processed identically to clinical samples, from culture setup through spectral acquisition and data analysis. Results from quality control strains should fall within established acceptance ranges. For semiquantitative growth curve analysis, the susceptible control should show the expected reduction in protein mass after antibiotic exposure, while the resistant control should show continued protein accumulation similar to the untreated control. If either control falls outside the expected range, the batch results should be considered invalid and the testing repeated.

Laboratories should track quality control results over time using Levey-Jennings charts or similar graphical tools. Trends in quality control values, even within acceptance ranges, can indicate developing problems with reagents, instrument calibration, or sample preparation procedures. The American Society for Microbiology provides educational resources on quality assurance practices that laboratories can adapt to MALDI-TOF MS-based AST.

Troubleshooting Common Spectral and Analytical Failures

When MALDI-TOF MS-based AST produces unexpected results, laboratories need a systematic approach to identify the cause. The first step is to assess spectral quality. Low signal intensity, high baseline noise, or inconsistent peak patterns suggest problems with sample preparation. Common causes include insufficient bacterial biomass, contamination with culture media components, improper matrix application, or inadequate extraction. Laboratories should establish minimum spectral quality criteria and reject spectra that do not meet these standards.

The second step is to review the growth conditions used for antibiotic exposure. Inoculum size, incubation time, and antibiotic concentration all affect the outcome of semiquantitative growth curve analysis. If the susceptible control shows inadequate growth inhibition, the inoculum may be too large or the incubation time too short. If the resistant control shows unexpected growth inhibition, the antibiotic concentration may be too high or the incubation time too long. Laboratories should document these parameters precisely and investigate any deviation from the standard operating procedure.

The third step is to examine the data analysis parameters. For machine learning approaches, the preprocessing steps, including baseline correction, peak alignment, and normalization, can significantly affect predictions. The 2025 review in Frontiers in Cellular and Infection Microbiology emphasized that effective management of high-dimensional data challenges is required for machine learning approaches to succeed. If a model that performed well during validation begins producing unexpected results, the preprocessing pipeline should be reviewed for changes or errors.

Recording Verification and Troubleshooting Data

Laboratories should maintain detailed records of verification studies and troubleshooting investigations. These records support regulatory compliance, proficiency testing, and continuous improvement. The following data should be documented for each verification study:

• Organism species and strain identifiers
• Source of each isolate, including reference culture collection numbers
• Antibiotics tested and concentrations used
• Reference method results and the specific method used
• MALDI-TOF MS-based AST results for each replicate
• Spectral quality metrics for each sample
• Discrepant results and the investigation findings
• Corrective actions taken and their outcomes

Troubleshooting records should follow a similar structure, documenting the problem observed, the investigation steps performed, the root cause identified, and the corrective action implemented. These records are valuable for training new personnel and for identifying recurring problems that may require changes to the standard operating procedure.

Establishing Escalation Criteria for Unresolved Discrepancies

When MALDI-TOF MS-based AST results cannot be resolved through troubleshooting, laboratories need clear escalation criteria. Discrepancies between MALDI-TOF MS-based results and conventional susceptibility testing should be investigated promptly. If the discrepancy involves a very major error, where a resistant isolate is reported as susceptible, the investigation should be prioritized because of the potential for treatment failure.

The investigation should include repeat testing by both methods, review of the isolate identification, and examination of the spectral data for quality issues. If the discrepancy persists after repeat testing, the isolate should be referred to a reference laboratory for confirmatory testing. The Clinical and Laboratory Standards Institute provides guidance on resolving discrepant susceptibility testing results that can be adapted for MALDI-TOF MS-based methods.

Laboratories should also establish criteria for pausing MALDI-TOF MS-based AST testing when problems cannot be resolved. If the rate of major or very major errors exceeds acceptable thresholds, or if quality control failures cannot be corrected, the laboratory should suspend MALDI-TOF MS-based AST and return to conventional methods until the problem is identified and resolved. This conservative approach protects patient safety while the laboratory works to restore method performance.

Integrating External Quality Assessment

External quality assessment programs provide an independent check on MALDI-TOF MS-based AST performance. These programs distribute unknown samples to participating laboratories and compare results across sites. Participation helps laboratories identify systematic errors that may not be apparent from internal quality control alone.

The World Health Organization emphasizes the importance of surveillance and laboratory capacity for addressing antimicrobial resistance globally. External quality assessment programs support this goal by ensuring that susceptibility testing results are reliable and comparable across laboratories. Laboratories implementing MALDI-TOF MS-based AST should participate in relevant external quality assessment programs and review their performance regularly.

When external quality assessment results reveal problems, the laboratory should conduct a root cause analysis and implement corrective actions. The findings should be documented and shared with relevant personnel. Repeated failures on external quality assessment should trigger a comprehensive review of the MALDI-TOF MS-based AST method, including consideration of whether the method is suitable for the laboratory's testing volume and organism mix.

Frequently Asked Questions

How does MALDI-TOF MS-based antimicrobial susceptibility testing differ from conventional methods?

Conventional susceptibility testing methods, such as broth microdilution and disk diffusion, rely on visible bacterial growth in the presence of antibiotics and typically require 16 to 24 hours after pure culture isolation. MALDI-TOF MS-based methods detect changes in bacterial protein profiles after brief antibiotic exposure, enabling results in 2 to 4 hours or less. The faster turnaround time allows clinicians to adjust therapy sooner, potentially improving patient outcomes.

What are the main approaches to MALDI-TOF MS-based AST?

Three main approaches exist. Resistance mechanism detection identifies characteristic spectral signatures associated with known resistance mechanisms. Semiquantitative growth curve analysis measures bacterial protein mass after brief antibiotic incubation to assess growth inhibition. Machine learning approaches use computational algorithms to identify spectral patterns that correlate with resistance or susceptibility without requiring prior knowledge of specific mechanisms.

How accurate is MALDI-TOF MS-based AST compared to conventional methods?

The accuracy of MALDI-TOF MS-based AST varies depending on the approach, the organism, and the antibiotic being tested. Studies have reported promising results, but the evidence base is still developing. A systematic review found that the quality of machine learning studies ranged from poor to very good, with limited external validation. Laboratories should validate MALDI-TOF MS-based AST methods against established reference methods before clinical use.

Can MALDI-TOF MS-based AST replace conventional susceptibility testing?

MALDI-TOF MS-based AST is not yet ready to replace conventional susceptibility testing for most applications. The method shows promise for reducing turnaround times, but limitations in standardization, validation, and generalizability remain. Laboratories should use MALDI-TOF MS-based AST as an adjunct to conventional methods, with confirmatory testing when results have major therapeutic implications.

What are the limitations of MALDI-TOF MS-based AST?

Current limitations include the need for pure cultures, challenges with fastidious organisms, limited validation for many organism-antibiotic combinations, and difficulties with data standardization. Machine learning approaches require large training datasets and may not generalize well to isolates from different geographic regions or clinical settings. Poor spectral quality and ambiguous results can also compromise accuracy.

How should laboratories validate MALDI-TOF MS-based AST methods?

Validation should follow Clinical and Laboratory Standards Institute guidelines and include testing a panel of well-characterized isolates with known susceptibility profiles. The panel should include both susceptible and resistant strains with diverse resistance mechanisms. Validation metrics should include sensitivity, specificity, positive predictive value, negative predictive value, categorical agreement, and essential agreement compared to reference methods.

What quality control measures are needed for MALDI-TOF MS-based AST?

Quality control measures include testing reference strains with known susceptibility profiles alongside clinical isolates, monitoring spectral quality metrics, performing regular instrument calibration and maintenance, and participating in proficiency testing programs. The American Type Culture Collection provides authenticated reference strains suitable for quality control purposes.

What are the biosafety considerations for MALDI-TOF MS-based AST?

Laboratories must follow appropriate biosafety practices when handling clinical bacterial isolates. The CDC and NIH Biosafety in Microbiological and Biomedical Laboratories manual provides guidance on risk assessment, containment, and decontamination. Sample preparation steps that may generate aerosols should be performed in biological safety cabinets, and personnel should use appropriate personal protective equipment.

Related Bacteriology Guides

• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Leptospirosis in Cattle: Clinical Syndromes and Diagnostic Approaches
• Chlamydiosis in Birds: Clinical Presentation and Advanced Diagnostic Methods
• Bacterial Infections in Poultry: Clinical Manifestations, Diagnosis, and Antimicrobial Therapy
• Swine Dysentery: Age Susceptibility, Causative Agent, and Clinical Management in Pigs

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Ad Hoc Antimicrobial Susceptibility Testing from MALDI-TOF MS Spectra in the Clinical Microbiology Laboratory.. Clinical chemistry, 2022.
• MALDI-TOF MS in conjunction with machine learning: toward a new era for antimicrobial susceptibility testing.. Frontiers in cellular and infection microbiology, 2025.
• Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans.. Antimicrobial agents and chemotherapy, 2015.
• Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.